Evaluation of prophylactic polyclonal anti‐D antibodies: Differences in Fc‐glycosylation in commercial products
Open Access
- 26 October 2021
- journal article
- letter
- Published by Wiley in Vox Sanguinis
- Vol. 117 (4) , 624-625
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Four keys to unlock IgGJournal of Experimental Medicine, 2021
- FIGO/ICM guidelines for preventing Rhesus disease: A call to actionInternational Journal of Gynecology & Obstetrics, 2020
- Anti-D monoclonal antibodies from 23 human and rodent cell lines display diverse IgG Fc-glycosylation profiles that determine their clinical efficacyScientific Reports, 2020
- Prophylactic anti‐D preparations display variable decreases in Fc‐fucosylation of anti‐DTransfusion, 2014
- Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti‐D immunoglobulin: more questions than answersVox Sanguinis, 2007